Click Therapeutics Announces Appointment of Top Ranked Healthcare Research Analyst Ross J. Muken as Chief Financial Officer
NEW YORK--Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced the appointment of Ross J. Muken as Chief Financial Officer. Mr. Muken brings to Click over 18 years of Wall Street experience and a distinguished track record of success, having been broadly recognized as a thought leader across the healthcare sector. Mr. Muken joins the Click team from Evercore ISI, where he was a Senior Managing Director and Partner.
“We are thrilled to welcome Ross to the leadership team,” said David Benshoof Klein, co-founder and CEO of Click. “Ross has had unrivaled insight into our industry since inception. His deep expertise across the healthcare continuum, strong relationships within the community, and wealth of experience will help us to capitalize on our leading position as we transition toward the next stage of rapid growth.”
“I’ve had the privilege of covering a number of disruptive technology companies in the healthcare space throughout my career, and Click is the most exciting opportunity I have come across to-date, with a clear path to becoming the leader in the digital therapeutics space,” said Ross J. Muken. “I am extremely impressed by the tremendous progress that Click has made in the past year and am pleased to join Click at this pivotal time as it is advancing several first-line digital therapeutics into the market. I look forward to leveraging my experience to support Click’s future growth and financial strategy as it builds upon the industry’s most advanced digital therapeutics and patient engagement platform.”
Ross J. Muken was previously Partner, Senior Managing Director and Head of the Healthcare Services & Technology Research Team at Evercore ISI, widely recognized as the #1 independent equity research franchise on Wall Street. He provided thoughtful insights on over 50 companies across the Healthcare Technology & Distribution, Life Science Tools & Diagnostics, Managed Care & Facilities and Medical Supplies & Devices sub-sectors. Ranked amongst the top analysts by Institutional Investor over the past decade, Mr. Muken is well-known for his proprietary fundamental research and highly accurate financial modeling as well as his work with emerging and disruptive technologies across the healthcare continuum. Prior to joining Evercore ISI, Mr. Muken served as a Managing Director at Deutsche Bank Securities, where he helped build the healthcare platform into a top franchise at the company. Previously, Mr. Muken spent time in the Equity Research division of Thomas Weisel Partners and began his career as an M&A Investment Banker at Bank of America Securities. Mr. Muken earned his B.S. in Business Administration, magna cum laude, at Boston University.
About Click Therapeutics
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including Major Depressive Disorder, Schizophrenia, Migraine, Multiple Sclerosis, Chronic Pain, Atopic Dermatitis, Acute Coronary Syndrome, Obesity, Oncology and more. For more information on Click, visit ClickTherapeutics.com.
Contacts
Company Contact
Sarah Jackson
Chief of Staff
sarah@clicktherapeutics.com
Media Contact
Karen Sharma
ksharma@macbiocom.com
781-235-3060